Abstract
Amifostine is a first-line cytoprotective drug used to prevent radiotherapy-induced or chemotherapy-induced injuries. However, its mechanism of action is not well understood. In this study, freshly harvested bone marrow cells were treated with amifostine and analyzed with a series of mitochondrial indices. In vitro results showed that bone marrow cells treated with amifostine 0.5 h before irradiation (0.5 Gy) experienced several benefits, as compared to vehicle controls, including (1) reduced reactive oxygen species levels, which reduced the production of free radicals; (2) better preservation of mitochondria, as indicated by MitoTracker-positive staining and the increased intensity of staining; (3) reduced apoptosis, as demonstrated by Annexin V staining; and (4) a better proliferation rate, as illustrated by MTT assay. Our in vitro studies showed that amifostine-treated mice exhibited (1) higher ATP production; (2) reduced plasma IL-2 levels, suppressing the immune response triggered by radiotoxicity; and (3) enhanced radiation-induced production of granulocyte colony-stimulating factor. All of these processes benefit recovery from radiation-induced damage.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ozcan Arican G (2005) Cytoprotective effects of amifostine and cysteamine on cultured normal and tumor cells treated with paclitaxel in terms of mitotic index and 3H-thymidine labeling index. Cancer Chemother Pharmacol 56(2):221–229
Hensley ML, Hagerty KL, Kewalramani T et al (2009) American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 27(1):127–145
Kouvaris JR, Kouloulias VE, Vlahos LJ (2007) Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist 12(6):738–747
Culy CR, Spencer CM (2001) Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 61(5):641–684
Capizzi RL, Scheffler BJ, Schein PS (1993) Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer 72(11):3495–3501
Invitrogen (2009) Amplex red hydrogen peroxide/peroxidase assay kit. http://probes.invitrogen.com/media/pis/mp22188.pdf. Updated 26 June 2009. Accessed 01 May 2013
Invitrogen (2008) MitoTracker mitochondrion-selective probes. https://www.ipmc.cnrs.fr/fichiers/recherche/microscopie/Sondes/MitoGreen.pdf. Updated 29 Mar 2013. Accessed 01 May 2013
Pape H, Orth K, Heese A et al (2006) G-CSF during large field radiotherapy reduces bone marrow recovery capacity. Eur J Med Res 11(8):322–328
Riley PA (1994) Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int J Radiat Biol 65(1):27–33
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this paper
Cite this paper
Lv, W. et al. (2013). Amifostine Acts Upon Mitochondria to Stimulate Growth of Bone Marrow and Regulate Cytokines. In: Van Huffel, S., Naulaers, G., Caicedo, A., Bruley, D.F., Harrison, D.K. (eds) Oxygen Transport to Tissue XXXV. Advances in Experimental Medicine and Biology, vol 789. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7411-1_27
Download citation
DOI: https://doi.org/10.1007/978-1-4614-7411-1_27
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-7256-8
Online ISBN: 978-1-4614-7411-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)